Smart RNA Delivery to Treat Eye Disease

Dr. Leblond has been a senior researcher at INSERM since 2019 and heads the ARNA Lab, where she leads the Targeted Aptamers, Medicines and Sensing group. Her background combines a strong foundation in chemistry with extensive experience in pharmaceutical sciences, focused on the development of advanced drug and gene delivery systems.
Her research focuses on the design of intelligent therapeutic delivery systems using lipid nanoparticles—similar to those used in mRNA vaccines—and aptamers, DNA or RNA sequences capable of recognizing specific targets in the body with high affinity and selectivity.
Before joining ARNA, she was an associate professor at the University of Montreal, where she developed pH-sensitive lipid nanoparticles for the efficient intracellular delivery of drugs and genetic material, one of the major current challenges in nanomedicine.
Currently, her group is working on the development of multifunctional nanocarriers that integrate molecular design, physicochemical characterization, and biological evaluation, with the aim of advancing toward clinical applications. This is an excellent opportunity to learn firsthand about cutting-edge advances in nanomedicine and RNA-based therapies.